Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort.

Ladas EJ, Orjuela M, Stevenson K, Cole PD, Lin M, Athale UH, Clavell LA, Leclerc JM, Laverdiere C, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM.

Clin Nutr. 2019 Jan 3. pii: S0261-5614(18)32589-5. doi: 10.1016/j.clnu.2018.12.021. [Epub ahead of print]

PMID:
30639117
2.

Psychological risk in long-term survivors of childhood acute lymphoblastic leukemia and its association with functional health status: A PETALE cohort study.

Anestin AS, Lippé S, Robaey P, Bertout L, Drouin S, Krajinovic M, Michon B, Rondeau É, Samoilenko M, Laverdière C, Sinnett D, Sultan S.

Pediatr Blood Cancer. 2018 Nov;65(11):e27356. doi: 10.1002/pbc.27356. Epub 2018 Aug 7.

PMID:
30084222
3.

Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.

Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB.

Blood Adv. 2018 Jun 26;2(12):1449-1458. doi: 10.1182/bloodadvances.2018016584.

4.

Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol.

Rae C, Furlong W, Feeny D, Couchman R, Silverman L, Sallan S, Laverdiere C, Clavell L, Michon B, Kelly K, Larsen E, Pullenayegum E, Athale U, Barr R.

J Pediatr Hematol Oncol. 2018 Nov;40(8):580-587. doi: 10.1097/MPH.0000000000001235.

PMID:
29901560
5.

Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.

Athale UH, Puligandla M, Stevenson KE, Asselin B, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Harris MH, Neuberg DS, Sallan SE, Silverman LB.

Pediatr Blood Cancer. 2018 Oct;65(10):e27256. doi: 10.1002/pbc.27256. Epub 2018 Jun 7.

PMID:
29878490
6.

Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.

Sulis ML, Blonquist TM, Stevenson KE, Hunt SK, Kay-Green S, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JG, Neuberg DS, Sallan SE, Silverman LB.

Pediatr Blood Cancer. 2018 Aug;65(8):e27082. doi: 10.1002/pbc.27082. Epub 2018 Apr 25. No abstract available.

PMID:
29693795
7.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.

Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Reshmi SC, Neuberg DS, Sallan SE, Loh ML, Silverman LB.

Blood Adv. 2018 Mar 13;2(5):529-533. doi: 10.1182/bloodadvances.2017014704.

8.

An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.

Kahn JM, Cole PD, Blonquist TM, Stevenson K, Jin Z, Barrera S, Davila R, Roberts E, Neuberg DS, Athale UH, Clavell LA, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Sallan SE, Silverman LB, Kelly KM.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26871. Epub 2017 Nov 1.

PMID:
29090520
9.

The clinical impact of copy number variants in inherited bone marrow failure syndromes.

Waespe N, Dhanraj S, Wahala M, Tsangaris E, Enbar T, Zlateska B, Li H, Klaassen RJ, Fernandez CV, Cuvelier GDE, Wu JK, Pastore YD, Silva M, Lipton JH, Brossard J, Michon B, Abish S, Steele M, Sinha R, Belletrutti MJ, Breakey VR, Jardine L, Goodyear L, Kofler L, Cada M, Sung L, Shago M, Scherer SW, Dror Y.

NPJ Genom Med. 2017 May 10;2. pii: 18. doi: 10.1038/s41525-017-0019-2.

10.

How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic.

Kahn JM, Athale UH, Clavell LA, Cole PD, Leclerc JM, Laverdiere C, Michon B, Schorin MA, Welch JJ, Sallan SE, Silverman LB, Kelly KM.

J Pediatr Health Care. 2017 Jan - Feb;31(1):e1-e6. doi: 10.1016/j.pedhc.2016.06.004. Epub 2016 Jul 25.

11.

Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study.

Ladas EJ, Orjuela M, Stevenson K, Cole PD, Lin M, Athale UH, Clavell LA, Leclerc JM, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM.

Nutrition. 2016 Oct;32(10):1103-1109.e1. doi: 10.1016/j.nut.2016.03.014. Epub 2016 Mar 28.

12.

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB.

Lancet Oncol. 2015 Dec;16(16):1677-90. doi: 10.1016/S1470-2045(15)00363-0. Epub 2015 Nov 6.

PMID:
26549586
13.

Impact of registration on clinical trials on infection risk in pediatric acute myeloid leukemia.

Dix D, Aplenc R, Bowes L, Cellot S, Ethier MC, Feusner J, Gillmeister B, Johnston DL, Lewis V, Michon B, Mitchell D, Portwine C, Price V, Silva M, Stobart K, Yanofsky R, Zelcer S, Beyene J, Sung L.

Int J Cancer. 2016 Apr 1;138(7):1785-91. doi: 10.1002/ijc.29905. Epub 2015 Nov 17.

14.

Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes.

Ghemlas I, Li H, Zlateska B, Klaassen R, Fernandez CV, Yanofsky RA, Wu J, Pastore Y, Silva M, Lipton JH, Brossard J, Michon B, Abish S, Steele M, Sinha R, Belletrutti M, Breakey VR, Jardine L, Goodyear L, Sung L, Dhanraj S, Reble E, Wagner A, Beyene J, Ray P, Meyn S, Cada M, Dror Y.

J Med Genet. 2015 Sep;52(9):575-84. doi: 10.1136/jmedgenet-2015-103270. Epub 2015 Jul 1.

PMID:
26136524
15.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators.

J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. Erratum in: J Clin Oncol. 2016 Nov 20;34(33):4059.

16.

The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.

Cada M, Segbefia CI, Klaassen R, Fernandez CV, Yanofsky RA, Wu J, Pastore Y, Silva M, Lipton JH, Brossard J, Michon B, Abish S, Steele M, Sinha R, Belletrutti M, Breakey V, Jardine L, Goodyear L, Sung L, Shago M, Beyene J, Sharma P, Zlateska B, Dror Y.

Haematologica. 2015 May;100(5):633-42. doi: 10.3324/haematol.2014.117457. Epub 2015 Feb 14.

17.

Second Bacteremia During Antibiotic Treatment in Children With Acute Myeloid Leukemia: A Report From the Canadian Infections in Acute Myeloid Leukemia Research Group.

Tran TH, Yanofsky R, Johnston DL, Dix D, Gillmeister B, Ethier MC, Portwine C, Price V, Mitchell D, Cellot S, Lewis V, Zelcer S, Silva M, Michon B, Bowes L, Stobart K, Brossard J, Beyene J, Sung L.

J Pediatric Infect Dis Soc. 2014 Sep;3(3):228-33. doi: 10.1093/jpids/pit086. Epub 2014 Jan 15.

PMID:
26625386
18.

Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group.

Tran TH, Mitchell D, Dix D, Cellot S, Ethier MC, Gillmeister B, Hitzler J, Lewis V, Yanofsky R, Johnston DL, Portwine C, Price V, Zelcer S, Silva M, Michon B, Bowes L, Stobart K, Brossard J, Beyene J, Sung L.

Infect Agent Cancer. 2013 Dec 2;8(1):47. doi: 10.1186/1750-9378-8-47.

19.

Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group.

Lewis V, Yanofsky R, Mitchell D, Dix D, Ethier MC, Gillmeister B, Johnston D, Michon B, Stobart K, Portwine C, Silva M, Cellot S, Price V, Bowes L, Zelcer S, Brossard J, Beyene J, Sung L.

Pediatr Infect Dis J. 2014 Feb;33(2):126-9. doi: 10.1097/INF.0000000000000058.

PMID:
24064558
20.

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.

Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB.

Cancer. 2013 Oct 1;119(19):3555-62. doi: 10.1002/cncr.28256. Epub 2013 Jul 16.

Supplemental Content

Loading ...
Support Center